22:10 , Mar 14, 2017 |  BC Extra  |  Company News

Blue Shield establishes practices for CED

Blue Shield of California has established new procedures for coverage with evidence development (CED), and looks to be among the first private commercial payers to adopt such a practice. CED has traditionally been used by...
07:00 , Mar 9, 2015 |  BioCentury  |  Strategy

Prepping for PCSK9s

By securing Priority Review for Praluent alirocumab, Sanofi and Regeneron Pharmaceuticals Inc. deprived Amgen Inc. of what could have been a three-month head start with its competing PCSK9 inhibitor. But the partners also put themselves...
02:08 , Jan 31, 2015 |  BC Extra  |  Company News

AbbVie forecasts $3B run rate for Viekira Pak

On its 4Q14 earnings call on Friday, AbbVie Inc. (NYSE:ABBV) forecast that it would achieve a global annualized sales run rate of $3 billion for HCV drug regimen Viekira Pak paritaprevir/ ritonavir / ombitasvir /...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Veracyte sales and marketing update

Veracyte said Blue Shield of California issued positive coverage decisions for Afirma Gene Expression Classifier . Afirma is a preoperative molecular diagnostic classifier based on genomic measurements from fine needle aspirate (FNA) samples to aid...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Sovaldi sofosbuvir regulatory update

Members of the California Technology Assessment Forum (CTAF) said that there is adequate evidence to support the superiority of Sovaldi sofosbuvir from Gilead Sciences and Olysio simeprevir from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.)...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Olysio simeprevir regulatory update

Members of the California Technology Assessment Forum (CTAF) said that there is adequate evidence to support the superiority of Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) and Olysio simeprevir from Johnson &...
00:50 , Mar 11, 2014 |  BC Extra  |  Politics & Policy

Group says HCV drugs effective, but lack value

Members of the California Technology Assessment Forum (CTAF) said on Monday that there is adequate evidence to support the superiority of Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) and Olysio simeprevir from Johnson & Johnson...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

CombiMatrix, Blue Shield of California sales and marketing update

CombiMatrix entered into a contract with health insurer Blue Shield of California to cover CombiMatrix's entire portfolio of testing services. CombiMatrix said the deal adds over 3 million covered lives, and in combination with the...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

MaterniT21 PLUS laboratory-developed test regulatory update

The not-for-profit California Technology Assessment Forum (CTAF) recommended use of Sequenom's MaterniT21 PLUS laboratory-developed test (LDT) to detect prenatal fetal chromosomal anomalies. Specifically, CTAF said the test meets criteria for safety, efficacy and improvement in...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Roche cancer news

Blue Shield of California said it will no longer cover Avastin bevacizumab for metastatic breast cancer, effective Oct. 17. The insurance provider, which did not provide a reason for the change, said exceptions may be...